Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Desloratadine Exposure and Incidence of Seizure: A Nordic Post-authorization Safety Study Using a New-User Cohort Study Design, 2001-2015

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Use of Pregabalin and Worsening Heart Failure: A Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of Proton Pump Inhibitors and the Risk of Acute Kidney Injury Among Patients with Rheumatoid Arthritis: Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment of Older Patients with Atrial Fibrillation by Morbidity Burden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Annette Kjær Ersbøll
  • Kaushik Sengupta
  • Eero Pukkala
  • Kristian Bolin
  • Eline Aas
  • Martha Emneus
  • Dena Rosen Ramey
  • Joanne E Brady
  • Daniel Mines
  • Kristian Aasbjerg
  • Christian Vestergaard
  • Gunnar Gislason
  • Alfred Peter Born
  • Thora Majlund Kjærulff
Vis graf over relationer

INTRODUCTION: A small number of adverse events of seizure in patients using desloratadine (DL) have been reported. The European Medicines Agency requested a post-authorization safety study to investigate whether there is an association between DL exposure and seizure.

OBJECTIVE: The aim was to study the association between DL exposure and incidence of first seizure.

METHODS: A new-user cohort study of individuals redeeming a first-ever prescription of DL in Denmark, Finland, Norway, and Sweden in 2001-2015 was conducted. DL exposure was defined as days' supply plus a 4-week grace period. DL unexposed periods were initiated 27 weeks after DL prescription redemption. Poisson regression was used to estimate the adjusted incidence rate and adjusted incidence rate ratio (aIRR) of incident seizure.

RESULTS: A total of 1,807,347 first-ever DL users were included in the study, with 49.3% male and a mean age of 29.5 years at inclusion; 20.3% were children aged 0-5 years. The adjusted incidence rates of seizure were 21.7 and 31.6 per 100,000 person-years during DL unexposed and exposed periods, respectively. A 46% increased incidence rate of seizure was found during DL exposed periods (aIRR = 1.46, 95% confidence interval [CI] 1.34-1.59). The aIRR ranged from 1.85 (95% CI 1.65-2.08) in children aged 0-5 years to 1.01 in adults aged 20 years or more (95% CI 0.85-1.19).

CONCLUSION: This study found an increased incidence rate of seizure during DL exposed periods as compared to unexposed periods among individuals younger than 20 years. No difference in incidence rate of seizure was observed in adults between DL exposed and unexposed.

OriginalsprogEngelsk
TidsskriftDrug Safety
Vol/bind44
Udgave nummer11
Sider (fra-til)1231-1242
Antal sider12
ISSN0114-5916
DOI
StatusUdgivet - nov. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 68332676